Yahoo India Web Search

Search results

  1. 1 day ago · Delhi's Lieutenant Governor VK Saxena on Thursday through his lawyers, requested the concerned court to award maximum punishment to Narmada Bachao Andolan (NBA) leader Medha Patkar in a criminal ...

  2. 2 days ago · VK Saxena. NEW DELHI: Lieutenant governor VK Saxena on Wednesday suspended Dr RN Das, the officer on special duty (OSD) to the Delhi health minister till further notice after allegations against ...

  3. 1 day ago · Delhi's Lieutenant Governor VK Saxena has requested maximum punishment for Narmada Bachao Andolan (NBA) leader Medha Patkar in a criminal defamation case filed against her. Patkar, who was the president of the National Council for Civil Liberties, had filed the defamation case in 2001 when she defamed him through a press release issued by her. The Saket District Court of Delhi recently convicted Patkar under Section 500 of the Indian Penal Code (IPC).

  4. 2 days ago · New Delhi: A Delhi court on Thursday adjourned the awarding of sentence to Narmada Bachao Andolan (NBA) activist Medha Patkar, who has been convicted in a defamation case filed by Delhi Lieutenant Governor (L-G) V.K. Saxena, to June 7. On May 24, Metropolitan Magistrate Raghav Sharma of Saket Courts convicted Patkar in the case, marking an ...

  5. 6 days ago · Delhi Lieutenant Governor VK Saxena completed two years since assuming charge as Lieutenant Governor of Delhi on Sunday. Mr. Saxena assumed the post of Delhi Lieutenant Governor on 26th May in 2022. In a social media post, Mr. Saxena shared his experience of work completed so far in the city.

  6. 5 days ago · New Delhi, May 26. Lieutenant-Governor (L-G) VK Saxena commemorated his two-year anniversary in office with a candid reflection on the challenges encountered during his tenure. Saxena, who...

  7. People also ask

  8. 2 days ago · Cancer patients with autoimmune disease have been excluded from randomized trials of immune checkpoint blockers (ICBs). We conducted a systematic review of observational studies and uncontrolled trials including cancer patients with pre-existing autoimmune disease who received ICIs.